PubMed:27130072
Annnotations
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-50 | Sentence | denotes | Angiogenic balance (sFlt-1/PlGF) and preeclampsia. |
T2 | 51-177 | Sentence | denotes | Preeclampsia is a hypertensive disorder of pregnancy associated with important maternal and perinatal mortality and morbidity. |
T3 | 178-369 | Sentence | denotes | Although symptomatic management has improved, there is currently no curative treatment, and only childbirth and delivery of the placenta, usually prematurely, alleviate the mother's symptoms. |
T4 | 370-454 | Sentence | denotes | Placental insufficiency plays a central role in the pathophysiology of preeclampsia. |
T5 | 455-565 | Sentence | denotes | Abnormal placentation during the first trimester leads to defective remodeling of the uterine vascularization. |
T6 | 566-817 | Sentence | denotes | This results progressively in placental hypoperfusion, which induces trophoblast dysfunction and the release in maternal circulation of trophoblastic factors leading to an excessive inflammatory response, endothelial dysfunction and glomerular damage. |
T7 | 818-1052 | Sentence | denotes | Among these factors, the most important is sFlt-1, which is a soluble form of the VEGF and PlGF receptor. sFlt-1 binds to free VEGF and PlGF in the maternal circulation, thus reducing their bioavailability for their membrane receptor. |
T8 | 1053-1154 | Sentence | denotes | The result is inhibition of the effects of VEGF and PlGF on maternal endothelial cells and podocytes. |
T9 | 1155-1268 | Sentence | denotes | The sFlt-1/PlGF ratio reflects the circulating angiogenic balance and is correlated with severity of the disease. |
T1 | 0-50 | Sentence | denotes | Angiogenic balance (sFlt-1/PlGF) and preeclampsia. |
T2 | 51-177 | Sentence | denotes | Preeclampsia is a hypertensive disorder of pregnancy associated with important maternal and perinatal mortality and morbidity. |
T3 | 178-369 | Sentence | denotes | Although symptomatic management has improved, there is currently no curative treatment, and only childbirth and delivery of the placenta, usually prematurely, alleviate the mother's symptoms. |
T4 | 370-454 | Sentence | denotes | Placental insufficiency plays a central role in the pathophysiology of preeclampsia. |
T5 | 455-565 | Sentence | denotes | Abnormal placentation during the first trimester leads to defective remodeling of the uterine vascularization. |
T6 | 566-817 | Sentence | denotes | This results progressively in placental hypoperfusion, which induces trophoblast dysfunction and the release in maternal circulation of trophoblastic factors leading to an excessive inflammatory response, endothelial dysfunction and glomerular damage. |
T7 | 818-1052 | Sentence | denotes | Among these factors, the most important is sFlt-1, which is a soluble form of the VEGF and PlGF receptor. sFlt-1 binds to free VEGF and PlGF in the maternal circulation, thus reducing their bioavailability for their membrane receptor. |
T8 | 1053-1154 | Sentence | denotes | The result is inhibition of the effects of VEGF and PlGF on maternal endothelial cells and podocytes. |
T9 | 1155-1268 | Sentence | denotes | The sFlt-1/PlGF ratio reflects the circulating angiogenic balance and is correlated with severity of the disease. |
Preeclampsia
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-Preeclampsia-B_T1 | 37-49 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T2 | 51-63 | ORPHA:275555 | denotes | Preeclampsia |
PD-Preeclampsia-B_T3 | 69-103 | ORPHA:275555 | denotes | hypertensive disorder of pregnancy |
PD-Preeclampsia-B_T4 | 441-453 | ORPHA:275555 | denotes | preeclampsia |
Preeclampsia-compare
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-Preeclampsia-B_T1 | 37-49 | ORPHA:275555 | denotes | preeclampsia |
PD-Preeclampsia-B_T2 | 51-63 | ORPHA:275555 | denotes | Preeclampsia |
PD-Preeclampsia-B_T3 | 69-103 | ORPHA:275555 | denotes | hypertensive disorder of pregnancy |
PD-Preeclampsia-B_T4 | 441-453 | ORPHA:275555 | denotes | preeclampsia |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-50 | Sentence | denotes | Angiogenic balance (sFlt-1/PlGF) and preeclampsia. |
TextSentencer_T2 | 51-177 | Sentence | denotes | Preeclampsia is a hypertensive disorder of pregnancy associated with important maternal and perinatal mortality and morbidity. |
TextSentencer_T3 | 178-369 | Sentence | denotes | Although symptomatic management has improved, there is currently no curative treatment, and only childbirth and delivery of the placenta, usually prematurely, alleviate the mother's symptoms. |
TextSentencer_T4 | 370-454 | Sentence | denotes | Placental insufficiency plays a central role in the pathophysiology of preeclampsia. |
TextSentencer_T5 | 455-565 | Sentence | denotes | Abnormal placentation during the first trimester leads to defective remodeling of the uterine vascularization. |
TextSentencer_T6 | 566-817 | Sentence | denotes | This results progressively in placental hypoperfusion, which induces trophoblast dysfunction and the release in maternal circulation of trophoblastic factors leading to an excessive inflammatory response, endothelial dysfunction and glomerular damage. |
TextSentencer_T7 | 818-1052 | Sentence | denotes | Among these factors, the most important is sFlt-1, which is a soluble form of the VEGF and PlGF receptor. sFlt-1 binds to free VEGF and PlGF in the maternal circulation, thus reducing their bioavailability for their membrane receptor. |
TextSentencer_T8 | 1053-1154 | Sentence | denotes | The result is inhibition of the effects of VEGF and PlGF on maternal endothelial cells and podocytes. |
TextSentencer_T9 | 1155-1268 | Sentence | denotes | The sFlt-1/PlGF ratio reflects the circulating angiogenic balance and is correlated with severity of the disease. |
T1 | 0-50 | Sentence | denotes | Angiogenic balance (sFlt-1/PlGF) and preeclampsia. |
T2 | 51-177 | Sentence | denotes | Preeclampsia is a hypertensive disorder of pregnancy associated with important maternal and perinatal mortality and morbidity. |
T3 | 178-369 | Sentence | denotes | Although symptomatic management has improved, there is currently no curative treatment, and only childbirth and delivery of the placenta, usually prematurely, alleviate the mother's symptoms. |
T4 | 370-454 | Sentence | denotes | Placental insufficiency plays a central role in the pathophysiology of preeclampsia. |
T5 | 455-565 | Sentence | denotes | Abnormal placentation during the first trimester leads to defective remodeling of the uterine vascularization. |
T6 | 566-817 | Sentence | denotes | This results progressively in placental hypoperfusion, which induces trophoblast dysfunction and the release in maternal circulation of trophoblastic factors leading to an excessive inflammatory response, endothelial dysfunction and glomerular damage. |
T7 | 818-1052 | Sentence | denotes | Among these factors, the most important is sFlt-1, which is a soluble form of the VEGF and PlGF receptor. sFlt-1 binds to free VEGF and PlGF in the maternal circulation, thus reducing their bioavailability for their membrane receptor. |
T8 | 1053-1154 | Sentence | denotes | The result is inhibition of the effects of VEGF and PlGF on maternal endothelial cells and podocytes. |
T9 | 1155-1268 | Sentence | denotes | The sFlt-1/PlGF ratio reflects the circulating angiogenic balance and is correlated with severity of the disease. |
UBERON-AE
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 306-314 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placenta |
PD-UBERON-AE-B_T2 | 402-409 | http://purl.obolibrary.org/obo/UBERON_0012131 | denotes | central |
PD-UBERON-AE-B_T3 | 635-646 | http://purl.obolibrary.org/obo/UBERON_0000088 | denotes | trophoblast |
PD-UBERON-AE-B_T4 | 702-715 | http://purl.obolibrary.org/obo/UBERON_0000088 | denotes | trophoblastic |
performance-test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 402-409 | http://purl.obolibrary.org/obo/UBERON_0012131 | denotes | central |
PD-UBERON-AE-B_T2 | 306-314 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placenta |
PD-UBERON-AE-B_T3 | 596-605 | http://purl.obolibrary.org/obo/UBERON_0001987 | denotes | placental |
PD-UBERON-AE-B_T4 | 635-646 | http://purl.obolibrary.org/obo/UBERON_0000088 | denotes | trophoblast |
PD-UBERON-AE-B_T5 | 702-715 | http://purl.obolibrary.org/obo/UBERON_0000088 | denotes | trophoblastic |